Press Releases April 12, 2026 08:00 PM

High Income Securities Fund Announces Monthly Distributions For Second Quarter of 2026

High Income Securities Fund declares monthly distributions for Q2 2026 under managed distribution plan

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
PCF

High Income Securities Fund (NYSE: PCF) announced its Board of Trustees has declared monthly distributions for April, May, and June 2026 at a fixed rate aligned with a 10% annual payout based on the Fund's net asset value as of the end of 2025. The distributions will be made under the Fund’s managed distribution plan, which allows for payments from net investment income, capital gains, or return of capital. The Fund may also issue an additional year-end distribution if income and gains exceed distributions made during the year.

High Income Securities Fund Announces Monthly Distributions For Second Quarter of 2026
PCF
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The Fund commits to a 10% annual distribution rate, paid monthly, based on a net asset value of $6.96 per share.
  • Distributions may include net investment income, capital gains, or return of capital, with composition detailed annually for tax purposes.
  • The Board retains the flexibility to amend or terminate the managed distribution plan at any time.

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- High Income Securities Fund (NYSE: PCF) (the “Fund”) today announced that the Fund’s Board of Trustees (the “Board”) has declared the next three monthly distributions under the Fund’s managed distribution plan.

Under the Fund’s managed distribution plan, the Fund intends to make monthly distributions to common stockholders at an annual rate of 10% (or 0.8333% per month) for 2026, based on the net asset value of $6.96 of the Fund’s common shares as of December 31, 2025.

The next three distributions declared under the managed distribution plan are as follows:

MonthRateRecord DatePayable DateApril$0.0580April 21, 2026April 30, 2026May$0.0580May 19, 2026May 29,2026June$0.0580June 16, 2026June 30, 2026    

Under the managed distribution plan, to the extent that sufficient investment income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital. To the extent that the Fund’s net investment income and net realized capital gains exceed the aggregate amount distributed pursuant to the managed distribution plan, the Fund may make an additional year-end distribution. No conclusions should be drawn about the Fund’s investment performance from the amount of the distributions. The Board may amend the terms of the managed distribution plan or terminate the plan at any time.

The Fund will issue a notice to stockholders that will provide an estimate of the composition of each distribution. For tax reporting purposes the actual composition of the total amount of distributions for each year will continue to be provided on a Form 1099-DIV issued after the end of the year.

Contact: Ultimus Fund Solutions, [email protected]


Risks

  • Distributions may include return of capital, which can reduce the Fund’s net asset value and potentially affect long-term returns.
  • If net investment income is insufficient, the Fund must use capital gains or return capital, which can impact distribution sustainability.
  • Market performance and interest rate changes can affect the Fund’s income and its ability to maintain distribution levels.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026